Asenapine - Generic Drug Details

What are the generic drug sources for asenapine and what is the scope of freedom to operate?

Asenapine is the generic ingredient in three branded drugs marketed by Hisamitsu, Alembic, Breckenridge, Sigmapharm Labs Llc, and Abbvie, and is included in five NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Asenapine has thirty-eight patent family members in nine countries.

There are twelve drug master file entries for asenapine. One supplier is listed for this compound.

Summary for asenapine

International Patents:	38
US Patents:	8
Tradenames:	3
Applicants:	5
NDAs:	5
Drug Master File Entries:	12
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	97
Clinical Trials:	55
Drug Prices:	Drug price trends for asenapine
What excipients (inactive ingredients) are in asenapine?	asenapine excipients list
DailyMed Link:	asenapine at DailyMed

See drug prices for asenapine

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for asenapine

Constraining patent/regulatory exclusivity:

11,813,364

Dosage:

SYSTEM;TRANSDERMAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for asenapine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Lindner Center of HOPE	Phase 2
Risk Benefit Statistics LLC
National Alliance on Mental Illness New Mexico

See all asenapine clinical trials

Pharmacology for asenapine

Drug Class

Atypical Antipsychotic

Anatomical Therapeutic Chemical (ATC) Classes for asenapine

N05AH	Diazepines, oxazepines, thiazepines and oxepines
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for asenapine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	SAPHRIS	asenapine maleate	TABLET;SUBLINGUAL	022117-001	Aug 13, 2009	AB	RX	Yes	No	8,022,228*PED				Y
Alembic	ASENAPINE MALEATE	asenapine maleate	TABLET;SUBLINGUAL	206098-001	Dec 10, 2020	AB	RX	No	No
Sigmapharm Labs Llc	ASENAPINE MALEATE	asenapine maleate	TABLET;SUBLINGUAL	206107-002	Dec 10, 2020	AB	RX	No	No
Hisamitsu	SECUADO	asenapine	SYSTEM;TRANSDERMAL	212268-002	Oct 11, 2019		RX	Yes	No	10,583,121		Y
Breckenridge	ASENAPINE MALEATE	asenapine maleate	TABLET;SUBLINGUAL	205960-001	Dec 10, 2020	AB	RX	No	No

EU/EMA Drug Approvals for asenapine

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
N.V. Organon	Sycrest	asenapine	EMEA/H/C/001177Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.	Authorised	no	no	no	2010-09-01

International Patents for asenapine

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2878298	TIMBRE ADHÉSIF ET SON PROCÉDÉ DE FABRICATION (ADHESIVE PATCH AND PRODUCTION METHOD THEREFOR)
South Korea	20150036478
South Korea	102013477
Japan	2017025111
Japan	WO2014017593	貼付剤及びその製造方法

Supplementary Protection Certificates for asenapine

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0746317	C300461	Netherlands		PRODUCT NAME: ASENAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MALEAAT; REGISTRATION NO/DATE: EU/1/10/640/001-006 20100901
0746317	SPC/GB10/046	United Kingdom		PRODUCT NAME: ASENAPINE; REGISTERED: UK EU/1/10/640/001 20100901; UK EU/1/10/640/002 20100901; UK EU/1/10/640/003 20100901; UK EU/1/10/640/004 20100901; UK EU/1/10/640/005 20100901; UK EU/1/10/640/006 20100901
0746317	10C0056	France		PRODUCT NAME: ASENAPINE; REGISTRATION NO/DATE: EU/1/10/640/001 20100901

Last updated: April 23, 2026

Asenapine (Drug Market Dynamics and Financial Trajectory)

Asenapine is an atypical antipsychotic with a concentrated commercial footprint driven by bipolar disorder demand, dosing-form convenience, and long-lived generic pressure in the U.S. market. Financial trajectory since launch has followed a classic pattern: early peak growth, then mature-market plateau as competition intensified, followed by erosion from generic entries and payer tightening. The current market dynamics are shaped by (1) the strength of bipolar indications versus schizophrenia in managed care, (2) the product’s distinctive sublingual administration that supports brand positioning versus some oral competitors, and (3) a regulatory and reimbursement environment that has increasingly favored lowest-cost equivalents as generics expanded.

---

What drives asenapine demand across key indications?

Asenapine is approved for:

• Bipolar I disorder (acute mania and maintenance)
• Schizophrenia
• Bipolar I disorder with mixed features (per labeling in relevant jurisdictions)

Commercial demand is typically higher in bipolar indications because these markets show tighter treatment pathways with fewer “off-label” swaps once a prescriber starts a patient on an antipsychotic plan. In practice, payer controls tend to target molecule-level costs and formulary tier placement, pushing volume toward the lowest net price after generic availability.

Form factor matters for conversion and persistence

• Asenapine’s sublingual delivery has historically helped differentiate it at the brand level and can support patient persistence where prescribers value the non-injection route.
• That said, when payers switch to generics, sublingual differentiation often loses value because coverage is primarily cost-driven.

Service and adherence

• Asenapine’s dosing regimen and administration rules (no food or drink for a period after administration in the core product instructions) affect patient routine. This can reduce persistence relative to once-daily agents, but it can still be defensible if the molecule is well-tolerated for individual patients.

---

How did the U.S. market evolve financially after branded launch?

Branded period: growth to peak and then plateau

Asenapine’s branded U.S. sales followed the typical branded antipsychotic cycle:

1. Launch-to-uptake driven by psychiatrist adoption and formulary inclusion.
2. Expansion via bipolar I disorder demand.
3. Plateau as managed care increasingly constrained incremental share via step therapy and tier movement.
4. Pressure as generic alternatives entered.

Generic era: pricing compression and volume substitution

Once generics entered, the economic trajectory shifted:

• Net price fell sharply due to generic competition.
• Share moved toward the lowest-cost equivalent within plan formularies.
• Total category spend often stabilized, but asenapine’s share of that spend typically declined versus higher-performing branded or newer branded competitors in adjacent antipsychotic segments.

Net effect: revenue contracted materially post-generic entry even when prescription volume remained resilient in some plans.

---

What role do generics and biosimilar-style competition pressures play (in antipsychotics)?

Antipsychotic competition is dominated by small-molecule generic substitution, not biologic-style interchange dynamics. For asenapine, the competitive pressure comes from:

• Multiple ANDA entrants once the reference product’s exclusivity cleared in the U.S.
• Broad insurer switching to generic equivalents.
• Pharmacy benefit manager (PBM) tactics such as preferred placement and rebate optimization, which compress branded economics and cap payers’ willingness to pay premium pricing.

Practical market outcome

• Even with clinical acceptability, asenapine faces hard limits on premium pricing once generics gain formularies.

---

What market dynamics shape global demand and financial performance?

Bipolar concentration and regional formulary behavior

Global sales mix depends on:

• How each region manages bipolar I disorder treatment pathways.
• Whether sublingual products hold formulary positioning.
• Availability and pricing of generics in each geography.

Patent and exclusivity timelines

Asenapine’s branded economics are also governed by:

• Patent coverage strength across key jurisdictions.
• Country-by-country generic launch timing once exclusivity periods ended.

The commercial trajectory for asenapine in many markets tracks the same pattern:

• Strong early uptake.
• Mature-market stabilization.
• Post-exclusivity decline driven by generic affordability and payer substitution.

---

Which financial metrics best capture asenapine’s trajectory?

For investment-grade assessment, the most decision-relevant metrics are:

1. U.S. prescription and market share trends (volume stability vs value compression)
2. Net sales versus list-price decline (to quantify rebate and PBM pressure)
3. Formulary tier and step-therapy patterns (to track access)
4. Generic penetration rate by month (to time the erosion curve)
5. Gross-to-net changes at the brand level (to estimate the branded margin squeeze)

A typical readout for asenapine post-generic is:

• Volume may remain present, but
• Value declines faster because generics replace branded economics.

---

Is asenapine still a meaningful commercial product?

Asenapine retains commercial relevance as an antipsychotic option, but its financial profile is primarily “mature”:

• It is no longer positioned as a high-growth brand after generic competition.
• In mature markets, asenapine functions as a cost-contained therapeutic option rather than a premium franchise.

From a business perspective, the molecule competes in a crowded antipsychotic landscape where access is often controlled by:

• Formulary preferences,
• Step-therapy requirements,
• and PBM-driven net price outcomes.

---

Key drivers vs. headwinds: what will move revenue next?

Primary revenue drivers

• Bipolar I disorder demand and ongoing prescribing for established patients.
• Patient-level persistence where asenapine has favorable tolerability.
• Formularies that allow generic entry without forcing molecule switches (some plans maintain multiple acceptable options).

Primary headwinds

• Generic cost pressure and continued rebate compression.
• Formulary restriction as PBMs optimize for lowest net cost.
• Therapeutic switching toward antipsychotics with preferred dosing convenience or better payer economics.

---

What does the U.S. generic timeline imply for the investment cycle?

The U.S. market implication is straightforward:

• The brand-to-generic transition is the primary inflection point.
• After generic penetration rises, sales typically remain at a lower value baseline while prescriptions may continue.

This matters for R&D and licensing decisions because it changes the expected ROI curve:

• Late-stage lifecycle expansion becomes less valuable if the molecule’s market value is structurally compressed by generic economics.
• New product positioning (new formulation, differentiated dosing, or label expansion) must overcome payer cost control, not just clinical differentiation.

---

Key Takeaways

• Asenapine’s commercial trajectory has been shaped by bipolar-driven demand early, followed by generic-driven value erosion in the U.S.
• The sublingual form factor supported brand differentiation, but payer substitution to generics caps branded financial upside in mature markets.
• Decision-grade view: expect volume resilience but revenue compression as generic penetration expands and formulary access tightens.
• Next financial movement is mostly determined by payer net pricing dynamics and formularies’ willingness to keep asenapine accessible versus pushing to other low-cost antipsychotics.

---

FAQs

1) What indication most supports asenapine demand?
Bipolar I disorder (acute and maintenance) is typically the main demand driver, with schizophrenia demand secondary and more exposed to formulary switching.

2) Does asenapine’s sublingual route create lasting pricing power?
It can support brand-level positioning, but pricing power is limited once generics enter and PBMs prioritize lowest net cost.

3) Why does asenapine revenue decline faster than prescriptions after generic entry?
Because gross-to-net and list-price reductions give way to lower-cost generic reimbursement while payer access shifts primarily on net price.

4) What are the most important commercial KPIs for asenapine now?
Net sales (value), prescriptions and share (volume), formulary tier status, and the pace of generic penetration.

5) What most impacts future revenue for asenapine?
Payer formulary decisions, step-therapy behavior, and ongoing generic price competition in the U.S.

---

References

[1] FDA. Saphris (asenapine maleate) prescribing information. U.S. Food and Drug Administration.
[2] DailyMed. Saphris (asenapine) label information. National Library of Medicine.
[3] FDA. Drug Approval Package: Saphris (asenapine). U.S. Food and Drug Administration.
[4] IQVIA. U.S. pharmaceutical market insights (antipsychotics; generic impact and net price dynamics). IQVIA (industry reporting).